Literature DB >> 29752657

Increased adiponectin is associated with cerebral white matter lesions in the elderly with cognitive impairment.

Youshi Fujita1, Takashi Toyomoto2, Tomomi Sakoh-Goshima2, Yutaka Kohno3, Masafumi Okada4, Tadanori Hamano5, Yasunari Nakamoto5.   

Abstract

Adiponectin is an adipocyte-derived peptide that increases with age and is thought to protect against atherosclerotic vascular changes and organ damage. However, paradoxically, higher adiponectin levels are associated with increased risk for cardiovascular events and mortality. We investigated whether this adiponectin paradox occurs in elderly people with cognitive impairment. Fifty-two elderly participants with mild cognitive impairment or dementia (20 male and 32 female, aged 60-93 years, mean 80.0) were recruited. We evaluated serum adiponectin levels and cerebral white matter lesions (WML), which are involved in cognitive decline and dementia, by computed tomography. Body mass index (BMI), Mini-Mental State Examination score, history of hypertension (HT), chronic kidney disease, and diabetes mellitus were also assessed. Stepwise multiple regression analysis was used to reveal the relationships between serum adiponectin and age, sex, BMI, HT, diabetes mellitus, chronic kidney disease, Mini-Mental State Examination, and WML scores. High serum adiponectin levels correlated with more severe WML (P = 0.013). Low BMI (P < 0.001), female sex (P = 0.025), and high WML scores (P = 0.039) were significant determinants of high serum adiponectin. HT (P = 0.032) and high adiponectin levels (P = 0.021) were independent risk factors for WML. Overall, we observed an association between serum adiponectin levels and WML severity in elderly people with cognitive decline. Our findings reveal that the adiponectin paradox occurs in this population, and this study may help guide future treatments for elderly people with mild cognitive impairment or dementia.

Entities:  

Keywords:  Adiponectin; Cerebral white matter lesions; Cognitive decline; Computed tomography; Dementia

Mesh:

Substances:

Year:  2018        PMID: 29752657     DOI: 10.1007/s11011-018-0247-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  22 in total

1.  Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease.

Authors:  K Une; Y A Takei; N Tomita; T Asamura; T Ohrui; K Furukawa; H Arai
Journal:  Eur J Neurol       Date:  2010-08-18       Impact factor: 6.089

2.  Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology".

Authors:  W Rathmann; C Herder
Journal:  Horm Metab Res       Date:  2007-01       Impact factor: 2.936

3.  Does adiponectin resistance exist in chronic heart failure?

Authors:  Ulrich Kintscher
Journal:  Eur Heart J       Date:  2007-06-25       Impact factor: 29.983

4.  Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging.

Authors:  Alexandra M V Wennberg; Deborah Gustafson; Clinton E Hagen; Rosebud O Roberts; David Knopman; Clifford Jack; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2016-05-04       Impact factor: 4.472

Review 5.  Brain adipocytokine action and metabolic regulation.

Authors:  Rexford S Ahima; Yong Qi; Neel S Singhal; Malaka B Jackson; Philipp E Scherer
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

6.  Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.

Authors:  M M Breteler; J C van Swieten; M L Bots; D E Grobbee; J J Claus; J H van den Hout; F van Harskamp; H L Tanghe; P T de Jong; J van Gijn
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

7.  Clinical characteristics of high plasma adiponectin and high plasma leptin as risk factors for arterial stiffness and related end-organ damage.

Authors:  Katsuhiko Kohara; Masayuki Ochi; Yoko Okada; Taiji Yamashita; Maya Ohara; Takeaki Kato; Tokihisa Nagai; Yasuharu Tabara; Michiya Igase; Tetsuro Miki
Journal:  Atherosclerosis       Date:  2014-06-03       Impact factor: 5.162

8.  Hypertension in the elderly is associated with white matter lesions and cognitive decline.

Authors:  J C van Swieten; G G Geyskes; M M Derix; B M Peeck; L M Ramos; J C van Latum; J van Gijn
Journal:  Ann Neurol       Date:  1991-12       Impact factor: 10.422

9.  Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study.

Authors:  Anna Maria Basile; Leonardo Pantoni; Giovanni Pracucci; Kjell Asplund; Hugues Chabriat; Timo Erkinjuntti; Franz Fazekas; José M Ferro; Michael Hennerici; John O'Brien; Philip Scheltens; Marieke C Visser; Lars-Olof Wahlund; Gunhild Waldemar; Anders Wallin; Domenico Inzitari
Journal:  Cerebrovasc Dis       Date:  2006-02-14       Impact factor: 2.762

Review 10.  Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease.

Authors:  Lavinia Woodward; Ioannis Akoumianakis; Charalambos Antoniades
Journal:  Br J Pharmacol       Date:  2016-10-19       Impact factor: 8.739

View more
  3 in total

1.  Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan: A Single-center, Retrospective Observational Study.

Authors:  Nobuhiro Akuzawa; Akihiro Yoshii; Akihiro Ono; Tomohito Kuwako; Takashi Osaki; Sho Osawa; Asuka Jingu; Satoru Watanabe; Ryusei Saito
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Oct-Dec       Impact factor: 2.703

2.  Adiponectin Levels Are Associated with White Matter Lesions (WMLs) and Cognitive Impairment.

Authors:  Hui Quan; Tongya Yu; Yingying Lin; Jie Pan; Bingjie Mao; Xuan Wang; Junchao Xie; Xueyuan Liu; Yanxin Zhao
Journal:  Biomed Res Int       Date:  2022-01-18       Impact factor: 3.411

3.  Links Between Adiponectin and Dementia: From Risk Factors to Pathophysiology.

Authors:  RuiJuan Chen; Yi Shu; Yi Zeng
Journal:  Front Aging Neurosci       Date:  2020-01-08       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.